China’s Diabetes Race Heats Up As Novo Pins Hopes On Human Insulin EDL Inclusion; Lilly Calls For Faster Coverage
This article was originally published in PharmAsia News
Executive Summary
As Novo, Sanofi and Lilly anxiously await listings for diabetes drugs on China’s Essential Drug List, most are readying themselves with patient education efforts to boost patient numbers and compliance.
You may also be interested in...
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.
Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports